AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Jun 5, 2024
30604_dirs_2024-06-05_9c3ae6ed-08aa-4591-aec7-fdfdf7438ae2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-06-03
Reporting Person: Scott Randal W. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-03 | Common Stock | S | 800 | $28.6844 | Disposed | 5700 | Indirect |
| 2024-06-03 | Common Stock | S | 200 | $29.475 | Disposed | 5500 | Indirect |
| 2024-06-04 | Common Stock | S | 1500 | $31.30 | Disposed | 4000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5000 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
F2: Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.